This HTML5 document contains 113 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-shhttp://sh.dbpedia.org/resource/
dcthttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n26https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
n18http://dbpedia.org/resource/List_of_drugs:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n20http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
dbpedia-srhttp://sr.dbpedia.org/resource/
dbpedia-pthttp://pt.dbpedia.org/resource/
n13http://azb.dbpedia.org/resource/
n12http://commons.wikimedia.org/wiki/Special:FilePath/
dbpedia-fahttp://fa.dbpedia.org/resource/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
dbpedia-frhttp://fr.dbpedia.org/resource/
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
n24http://dbpedia.org/resource/PI3K/AKT/
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Alkyl-lysophospholipids
dbo:wikiPageWikiLink
dbr:Perifosine
Subject Item
dbr:Perifosine
rdf:type
dbo:ChemicalCompound yago:Matter100020827 yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 yago:Macromolecule114944888 yago:WikicatOrganophosphates yago:OrganicCompound114727670 dbo:ChemicalSubstance yago:Organophosphate114969994 n20:ChemicalObject dbo:Person yago:Lipid114938907 yago:Abstraction100002137 yago:Material114580897 wikidata:Q11173 yago:Molecule114682133 yago:Chemical114806838 yago:Phospholipid114982681 yago:WikicatPhospholipids yago:PhysicalEntity100001930 yago:Relation100031921 yago:Pesticide114980215 yago:Part113809207 yago:WikicatQuaternaryAmmoniumCompounds yago:Compound114818238 owl:Thing yago:Insecticide114919948 yago:QuaternaryAmmoniumCompound114691231
rdfs:label
Perifosina Perifosine Périfosine
rdfs:comment
La périfosine est un alkyl-lysophospholipide apparenté structurellement à la miltéfosine et agissant comme inhibiteur enzymatique de la protéine kinase B (Akt) et des phosphoinositide 3-kinases (PI3K). Il est en essai clinique comme médicament phospholipidique potentiel et était en étude pivot (phase III) en 2011 comme traitement contre la maladie de Kahler et le cancer du côlon ; le 2 avril 2012 était cependant annoncé que la périfosine n'avait pas passé la phase III comme traitement contre le cancer du côlon. Perifosina (DCI; ou KRX-0401) é um fármaco antineoplásico desenvolvido pela Keryx Biopharmaceuticals e Aeterna Zentaris. Recebeu estatuto de medicamento órfão pelo FDA em julho de 2010, para tratamento de neuroblastoma. É um fármaco oncológico, utilizado no tratamento de mieloma múltiplo, câncer colorretal metatástico, câncer de rim e outros tipos de câncer. Aeterna Zentaris possui direitos de comercialização do fármaco em todos países exceto EUA (área da Keryx) e Coreia do Sul. Perifosine (also KRX-0401) is a former drug candidate that was under development for a variety of cancer indications. It is an alkyl-phospholipid structurally related to miltefosine. Perifosine interrupts the PI3K/AKT/mTOR pathway by acting as an allosteric AKT inhibitor targeting the pleckstrin homology domain of AKT. It was being developed by Keryx Biopharmaceuticals who had licensed it from Inc. In 2010, perifosine received orphan drug status in the U.S. for the treatment of multiple myeloma and neuroblastoma, and for multiple myeloma in the EU. However, both were later withdrawn.
foaf:depiction
n12:Perifosine-zwitterion-3D-spacefill.png n12:Perifosine.svg
dct:subject
dbc:Zwitterions dbc:Phospholipids dbc:Withdrawn_drugs dbc:Protein_kinase_inhibitors dbc:Quaternary_ammonium_compounds dbc:Abandoned_drugs dbc:Experimental_drugs dbc:Organophosphates
dbo:wikiPageID
31032459
dbo:wikiPageRevisionID
1105637098
dbo:wikiPageWikiLink
dbc:Phospholipids dbc:Organophosphates dbc:Withdrawn_drugs dbc:Experimental_drugs dbr:Pleckstrin_homology_domain dbr:Neuroblastoma dbc:Protein_kinase_inhibitors dbr:Phospholipid dbr:Miltefosine dbc:Quaternary_ammonium_compounds dbr:Æterna_Zentaris dbr:Orphan_drug n24:mTOR_pathway dbr:Colorectal_cancer dbr:AKT_inhibitor dbc:Abandoned_drugs dbr:Allosteric dbc:Zwitterions dbr:Multiple_myeloma
owl:sameAs
dbpedia-pt:Perifosina n13:پریفوسین dbpedia-sr:Perifozin freebase:m.0gg9fv_ wikidata:Q3411917 yago-res:Perifosine dbpedia-sh:Perifozin n26:39Qz5 dbpedia-fr:Périfosine dbpedia-fa:پریفوسین
dbp:wikiPageUsesTemplate
dbt:Chembox_Properties dbt:Chembox_Hazards dbt:Chembox_Identifiers dbt:Chembox dbt:Reflist dbt:Fdacite dbt:Chembox_Pharmacology dbt:Cascite
dbo:thumbnail
n12:Perifosine.svg?width=300
dbp:imagealt
Space-filling model of the perifosine zwitterion Skeletal formula of perifosine
dbp:imagefile
Perifosine.svg Perifosine-zwitterion-3D-spacefill.png
dbp:imagesize
320 300
dbp:iupacname
11
dbp:othernames
D 21266; KRX 0401
dbo:abstract
La périfosine est un alkyl-lysophospholipide apparenté structurellement à la miltéfosine et agissant comme inhibiteur enzymatique de la protéine kinase B (Akt) et des phosphoinositide 3-kinases (PI3K). Il est en essai clinique comme médicament phospholipidique potentiel et était en étude pivot (phase III) en 2011 comme traitement contre la maladie de Kahler et le cancer du côlon ; le 2 avril 2012 était cependant annoncé que la périfosine n'avait pas passé la phase III comme traitement contre le cancer du côlon. Perifosina (DCI; ou KRX-0401) é um fármaco antineoplásico desenvolvido pela Keryx Biopharmaceuticals e Aeterna Zentaris. Recebeu estatuto de medicamento órfão pelo FDA em julho de 2010, para tratamento de neuroblastoma. É um fármaco oncológico, utilizado no tratamento de mieloma múltiplo, câncer colorretal metatástico, câncer de rim e outros tipos de câncer. Aeterna Zentaris possui direitos de comercialização do fármaco em todos países exceto EUA (área da Keryx) e Coreia do Sul. Perifosine (also KRX-0401) is a former drug candidate that was under development for a variety of cancer indications. It is an alkyl-phospholipid structurally related to miltefosine. Perifosine interrupts the PI3K/AKT/mTOR pathway by acting as an allosteric AKT inhibitor targeting the pleckstrin homology domain of AKT. It was being developed by Keryx Biopharmaceuticals who had licensed it from Inc. In 2010, perifosine received orphan drug status in the U.S. for the treatment of multiple myeloma and neuroblastoma, and for multiple myeloma in the EU. However, both were later withdrawn. In 2011 it was in a phase III trial for colorectal cancer, and another for multiple myeloma. On April 2, 2012, it was announced that perifosine failed its phase III clinical trial for treatment of colon cancer. Detailed results were released in June 2012. On March 11, 2013 Aeterna Zentaris announced the discontinuing of Phase 3 clinical trial of perifosine for the treatment of relapsed and refractory multiple myeloma.
gold:hypernym
dbr:Candidate
prov:wasDerivedFrom
wikipedia-en:Perifosine?oldid=1105637098&ns=0
dbo:wikiPageLength
5635
dbo:alternativeName
D 21266; KRX 0401
dbo:iupacName
1,1-Dimethylpiperidinium-4-yl octadecyl phosphate
foaf:isPrimaryTopicOf
wikipedia-en:Perifosine
Subject Item
dbr:Index_of_oncology_articles
dbo:wikiPageWikiLink
dbr:Perifosine
Subject Item
dbr:Lysophosphatidylcholine
dbo:wikiPageWikiLink
dbr:Perifosine
Subject Item
dbr:Protein_kinase_B
dbo:wikiPageWikiLink
dbr:Perifosine
Subject Item
dbr:Edelfosine
dbo:wikiPageWikiLink
dbr:Perifosine
Subject Item
dbr:Targeted_therapy
dbo:wikiPageWikiLink
dbr:Perifosine
Subject Item
dbr:RICTOR
dbo:wikiPageWikiLink
dbr:Perifosine
Subject Item
n18:_Pb–Pe
dbo:wikiPageWikiLink
dbr:Perifosine
Subject Item
dbr:KRX-0401
dbo:wikiPageWikiLink
dbr:Perifosine
dbo:wikiPageRedirects
dbr:Perifosine
Subject Item
wikipedia-en:Perifosine
foaf:primaryTopic
dbr:Perifosine